|
| 36703796 | Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. | Front Oncol | 2023 |
| 37207300 | Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. | J Clin Oncol | 2023 |
| 35022867 | Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer. | Breast Cancer Res Treat | 2022 |
| 34169393 | Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. | Breast Cancer Res Treat | 2021 |
| 33727258 | Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. | Clin Cancer Res | 2021 |
| 34782665 | Alterations of the 70Â kDa heat shock protein (HSP70) and sequestosome-1 (p62) in women with breast cancer. | Sci Rep | 2021 |
| 34426581 | Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer. | NPJ Breast Cancer | 2021 |
| 34602950 | Expert Discussion: HER2-Positive Breast Cancer. | Breast Care (Basel) | 2021 |
| 32452601 | Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. | Oncologist | 2020 |
| 33841882 | Endocrine Therapy-related Endocrinopathies-Biology, Prevalence and Implications for the Management of Breast Cancer. | Oncol Hematol Rev | 2020 |
| 31968251 | Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. | Cell Rep | 2020 |
| 32667883 | Three-dimensional growth of breast cancer cells potentiates the anti-tumor effects of unacylated ghrelin and AZP-531. | Elife | 2020 |
| 32612958 | Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. | Front Oncol | 2020 |
| 31592503 | Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. | JCO Precis Oncol | 2019 |
| 28935542 | Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. | Clin Breast Cancer | 2018 |
| 30069183 | PARP Inhibitors in Breast Cancer: Why, How, and When? | Breast Care (Basel) | 2018 |
| 29736694 | Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial. | Clin Transl Oncol | 2018 |
| 28654428 | Residual Pure Intralymphatic Breast Carcinoma Following Neoadjuvant Chemotherapy Is Indicative of Poor Clinical Outcome, Even in Node-Negative Patients. | Am J Surg Pathol | 2017 |
| 28611537 | Therapeutic Advances and New Directions for Triple-Negative Breast Cancer. | Breast Care (Basel) | 2017 |
| 28721390 | Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. | NPJ Breast Cancer | 2016 |
| 25572591 | Circulating tumor cells in newly diagnosed inflammatory breast cancer. | Breast Cancer Res | 2015 |
| 25881743 | Therapies for triple negative breast cancer. | Expert Opin Pharmacother | 2015 |
| 24903226 | A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. | Breast Cancer Res Treat | 2014 |
| 25254601 | Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer. | Cancer Invest | 2014 |
| 23440080 | Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview. | Curr Breast Cancer Rep | 2013 |
| 24068539 | Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. | Breast Cancer Res Treat | 2013 |
| 23633449 | Breast cancer genomics: challenges in interpretation and application. | Oncologist | 2013 |
| 21469140 | Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detectâ¿¢ versus Veridex CellSearchâ¿¢ system. | Int J Cancer | 2012 |
| 22493366 | A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density. | Anticancer Res | 2012 |
| 22622148 | Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer? | Oncologist | 2012 |
| 21965473 | Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. | Ann Oncol | 2012 |
| 20857493 | Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. | Int J Cancer | 2011 |
| 21558518 | A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. | JAMA | 2011 |
| 21406473 | Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? | Ann Oncol | 2011 |
| 21456383 | Seeing red: anthracyclines for breast cancer. | Oncology (Williston Park) | 2011 |
| 21069334 | Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer. | Cancer Chemother Pharmacol | 2011 |
| 20189874 | Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. | Lancet Oncol | 2010 |
| 20944093 | Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer. | Anticancer Res | 2010 |
| 20439340 | Incidence of and survival following brain metastases among women with inflammatory breast cancer. | Ann Oncol | 2010 |
| 20564098 | Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. | Cancer | 2010 |
| 20131993 | Circulating tumor cells as prognostic marker in metastatic breast cancer. | Expert Rev Anticancer Ther | 2010 |
| 19451443 | Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. | J Clin Oncol | 2009 |
| 19888227 | Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. | Br J Cancer | 2009 |
| 19556320 | Circulating tumor cells in metastatic inflammatory breast cancer. | Ann Oncol | 2009 |
| 18669447 | Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. | J Clin Oncol | 2008 |
| 29783493 | Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stage. | Per Med | 2008 |
| 21892319 | Documentation of complete response in metastatic breast cancer to liver and bone achieved with trastuzumab and pegylated liposomal Doxorubicin. | Clin Med Oncol | 2008 |
| 18637400 | Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes. | Clin Breast Cancer | 2008 |
| 17301073 | Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. | Ann Oncol | 2007 |
| 17919349 | Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. | Clin Breast Cancer | 2007 |